Middle East And Africa Continuous Glucose Monitoring Market Size

Middle East and Africa Continuous Glucose Monitoring Market Analysis

The Middle East And Africa Continuous Glucose Monitoring Market size is estimated at USD 261.03 million in 2024, and is expected to reach USD 477.33 million by 2029, growing at a CAGR of 12.83% during the forecast period (2024-2029).

The Middle East and Africa Continuous Glucose Monitoring Market size is estimated at USD 261.03 million in 2024, and is expected to reach USD 477.33 million by 2029, growing at a CAGR of 12.83% during the forecast period (2024-2029).

During the COVID-19 pandemic patients with diabetes, infected experienced additional stress and increased secretion of hyperglycemic hormones. To avoid aggravation, a patient's blood glucose monitoring had to be considered during the COVID-19 patient's hospitalization which highlighted the importance of continuous glucose monitoring devices. Pandemic emergency created a surge in remote care from both patients and providers and removed many long-standing regulatory barriers. Thus, the COVID-19 outbreak increased the continuous glucose monitoring device market's growth.

73 million adults (20-79) are living with diabetes in the IDF MENA Region in 2021. This figure is estimated to increase to 95 million by 2030. 48 million adults in the IDF MENA Region are living with Impaired Glucose Tolerance, which places them at increased risk of developing type 2 diabetes. Diabetes is responsible for 796,000 deaths in the IDF MENA Region in 2021. USD 33 billion was spent on healthcare for people with diabetes in 2021.

The Middle East and African region had witnessed an alarming increase in the prevalence of diabetes, in recent years, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates by monitoring their blood glucose levels. Diabetes poses an emerging healthcare burden across the region The Type 1 diabetes population completely depends on insulin therapy. Therefore, they constantly need to monitor their blood glucose levels. Some Type 2 diabetes patients also depend on insulin therapy and 90% of the diabetic population is type 2, most of them use Continuous glucose monitoring devices to monitor their insulin levels.

Owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.